This presentation is delivered by GossamerBio, an industry partner of PHA Europe. They are in the process of developing a new PH medication that is based on a well-established component and is administered as an inhaled drug. During the presentation, Gossamer provides details about their drug and discusses their TORREY phase 2 study. The presentation concludes with an engaging Q&A session lasting almost 56 (!) minutes.